
Fw: daptomycin resistant isolates, and a proposed isolate biobank

1 message

Geoffrey Coombs <G.Coombs@murdoch.edu.au>
To: Geoffrey Coombs <geoff@asainc.net.au>

5 April 2023 at 13:14

Professor Geoffrey Coombs PhD, FASM, RCPA FFSc, FISAC**Chair of Public Health** | College of Science, Health, Engineering and Education, Murdoch University**Room 2-037, Building 240, 90 South Street, Murdoch WA 6150****Senior Clinical Scientist** | PathWest Laboratory Medicine - WA, Fiona Stanley Hospital**President** | Australian Society for Antimicrobials (www.asainc.net.au)**Chair** | Australian Group on Antimicrobial Resistance (www.agargroup.org)**President** | International Society of Antimicrobial Chemotherapy (www.isac.world)

Monday	Tuesday	Wednesday	Thursday	Friday
		8:30-16:30	8:30-16:30	8:30-16:30



I **acknowledge** that Murdoch University is situated on the lands of the Whadjuk and Binjareb Noongar people. I pay my respect to their enduring and dynamic culture and the leadership of Noongar elders past and present. The boodjar (country) on which Murdoch University is located has for thousands of years, been a place of learning. We at Murdoch University are proud to continue this long tradition.

CRICOS Provider Code: 00125J

This email and any files transmitted with it are confidential and intended solely for the use of the individual or entity to whom they are addressed. If you have received this email in error, please notify the sender. Please note that any views or opinions presented in this email are solely those of the author and do not necessarily represent those of Murdoch University. Finally, the recipient should check this email and any associated files for the presence of viruses. Murdoch University accepts no liability for any damage caused by any virus transmitted by this email.

From: Jonathan Iredell <jonathan.iredell@sydney.edu.au>**Sent:** Wednesday, 5 April 2023 12:33 PM**To:** Geoffrey Coombs <G.Coombs@murdoch.edu.au>; Mark Blaskovich <m.blaskovich@imb.uq.edu.au>**Subject:** RE: daptomycin resistant isolates, and a proposed isolate biobank

Thx Geoff Hi Mark

There are lots of public sector biobanking initiatives on foot.

Big public health labs like ICPMR (NSW ref lab) are trying to do this so that drug discovery folks like yourself have good access.

Kind regards
Jon Iredell

From: Geoffrey Coombs <G.Coombs@murdoch.edu.au>
Sent: Wednesday, April 5, 2023 12:25 PM
To: Mark Blaskovich <m.blaskovich@imb.uq.edu.au>
Cc: Jonathan Iredell <jonathan.iredell@sydney.edu.au>
Subject: Re: daptomycin resistant isolates, and a proposed isolate biobank

Hi Mark

Sorry about the delay in getting back to you - never enough hours in the week

Regarding the DNSSA

The student is currently writing a manuscript (as part of her PhD) on the work presented at ASA

Could I get back to you once the manuscript has been accepted

As you probably can appreciate, she is planning to do a lot more work on these isolates

Regarding biobank

Happy to discuss further

I fly to Europe on Tuesday 11 April for ECCMID and will be away for two weeks

Can we catch up when I get back

FYI

With the AGAR isolates all the *S. aureus* and Enterococcus are referred to my lab and selected GNB referred to Jon Iredell's lab

Might be worth discussing with me and Jon

Kind regards

Geoff

Professor Geoffrey Coombs PhD, FASM, RCPA FFSc, FISAC

Chair of Public Health | College of Science, Health, Engineering and Education, Murdoch University

Room 2-037, Building 240, 90 South Street, Murdoch WA 6150

Senior Clinical Scientist | PathWest Laboratory Medicine - WA, Fiona Stanley Hospital

President | Australian Society for Antimicrobials (www.asainc.net.au)

Chair | Australian Group on Antimicrobial Resistance (www.agargroup.org)

President | International Society of Antimicrobial Chemotherapy (www.isac.world)

Monday	Tuesday	Wednesday	Thursday	Friday
		8:30-16:30	8:30-16:30	8:30-16:30



I acknowledge that Murdoch University is situated on the lands of the Whadjuk and Binjareb Noongar people. I pay my respect to their enduring and dynamic culture and the leadership of Noongar elders past and present. The boodjar (country) on which Murdoch University is located has for thousands of years, been a place of learning. We at Murdoch University are proud to continue this long tradition.

CRICOS Provider Code: 00125J

This email and any files transmitted with it are confidential and intended solely for the use of the individual or entity to whom they are addressed. If you have received this email in error, please notify the sender. Please note that any views or opinions presented in this email are solely those of the author and do not necessarily represent those of Murdoch University. Finally, the recipient should check this email and any associated files for the presence of viruses. Murdoch University accepts no liability for any damage caused by any virus transmitted by this email.

From: Mark Blaskovich <m.blaskovich@imb.uq.edu.au>
Sent: Wednesday, 29 March 2023 3:48 PM
To: Geoffrey Coombs <G.Coombs@murdoch.edu.au>
Subject: daptomycin resistant isolates, and a proposed isolate biobank

Dear Geoff,

It was a pleasure to meet you at ASA. I was wanting to follow up on your student's poster on daptomycin resistant isolates - as I mentioned at the time, we've got a daptomycin-derived fluorescent probe that we're trying to see if it can distinguish between resistant/sensitive isolates, so would be very interested in testing against your collection, if you were able to share. We'd be particularly interested if any of them had significantly higher MICs (e.g. > 4), and/or a representative set of different mutations.

Separately, was at a One Health summit in Adelaide the other week, and was chatting with Jan Bell and John Turnidge about a project we've been working on, and they suggested having a chat with you under your AGAR hat. As part of one of our CARB-X projects, we have collected >800 MDR/XDR isolates from LMICs (focused on polymyxin resistance) which are undergoing full sequencing (Illumina done, starting on Nanopore) and phenotypic profiling (Vitek done, full BMD antibiograms vs 40+ antibiotics in progress), with the data to be deposited in a publically accessible database (existing repositories, along with a bespoke one...). Eventually, we'd also like to make the isolates available for others to access, though that requires some contract renegotiations with the LMICs.

What we'd like to do is extend the concept and build up an Australian biobank equivalent, collecting resistant isolates annually so we have a geographical and temporal biobank, with full characterisation, and with isolates available for other researchers to access to e.g. test new antibiotics, resistance mechanism studies etc. . The approx 1500 annual isolates identified by CARAlert seems like a potential starting point, otherwise building up a network of pathology labs willing to contribute isolates to provide a snapshot of a range of species and resistance.

Does this concept have any merit in your eyes? If so, would AGAR be willing to help support funding applications? There are some MRFF and NIH (or possibly NCRIS) opportunities where it sort of meets eligibility criteria...

Best regards,

Mark

Prof Mark Blaskovich

Professorial Research Fellow & Group Leader

Director of Translation

Institute for Molecular Bioscience

306 Carmody Road (Building 80)

The University of Queensland

Brisbane Qld 4072 Australia

T +61 7 3346 2039 M +61 414 955 380

E m.blaskovich@uq.edu.au W uq.edu.au

Skype [mark.blaskovich.imb](https://www.skype.com/people/mark.blaskovich.imb) **Blaskovich Researcher Profile** **BlaskoGroup**

ORCID | ResearcherID | Scopus | Google Scholar | UQ eSpace | ResearchGate | LinkedIn | Twitter: [@mark_blaskovich](https://twitter.com/mark_blaskovich)

I work on a flexible work schedule and across a number of time zones so I'm sending this message now because it works for me. Feel free to read, act on or respond at a time that works for you.



Connect: imb.uq.edu.au | [Subscribe](#) | [Facebook](#) | [Twitter](#)

This email (including any attached files) is intended solely for the addressee. It may contain private or confidential information. If you are not the intended addressee, you must take no action based on it, nor show a copy to anyone. Kindly notify the sender by reply email. Opinions and information in this email which do not relate to the official business of The University of Queensland shall be understood as neither given nor endorsed by the University. CRICOS Provider Number 00025B.